Biomedical Advanced Research and Development Authority (BARDA) has awarded Tetraphase Pharmaceuticals a contract with a total value of $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens. TP-434 is Tetraphase’s lead product candidate. Tetraphase will be work on this contract with CUBRC, Inc., based in Buffalo, NY. The contract includes preclinical efficacy and toxicology studies, clinical studies, manufacturing, ...